Department of Surgery, Unity Health Toronto, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
BMJ Open. 2020 Sep 13;10(9):e038621. doi: 10.1136/bmjopen-2020-038621.
The patient experience is a critical dimension of colonoscopy quality. Sedative and analgesic drugs are commonly used to improve the patient experience of colonoscopy, with predominant regimens being deep sedation, typically achieved with propofol, and moderate sedation, typically achieved with an opioid and a benzodiazepine. However, non-pharmacological interventions exist that may be used to improve patient experience. Furthermore, by identifying non-pharmacological interventions to increase the quality of patient experience under moderate sedation, jurisdictions facing rising use of deep sedation for colonoscopy and its significant associated costs may be better able to encourage patients and clinicians to adopt moderate sedation. Advancing either of these aims requires synthesising the evidence and raising awareness around these non-pharmacological interventions to improve the patient experience of colonoscopy.
A systematic review will be conducted that searches multiple electronic databases from inception until 2020 to identify randomised controlled trials evaluating what, if any, non-pharmacological interventions are effective compared with placebo or usual care for improving the patient experience of routine colonoscopy under moderate or no sedation. Two reviewers will independently perform a three-stage screening process and extract all study data using piloted forms. Study quality will be assessed using the Cochrane Risk of Bias Tool V.2.0. Where multiple studies evaluate a single intervention, evidence will be quantitatively synthesised using pairwise meta-analysis, otherwise narrative syntheses will be undertaken.
This is a review of existing literature not requiring ethics approval. The review findings will be included in future efforts to develop an implementation strategy to reduce the use of deep sedation for routine colonoscopy. They will also be published in a peer-reviewed journal, presented at conferences and contribute to a doctoral thesis.
CRD42020173906.
患者体验是结肠镜检查质量的一个关键维度。镇静和镇痛药物通常被用于改善结肠镜检查的患者体验,主要方案为深度镇静,通常使用丙泊酚实现,以及中度镇静,通常使用阿片类药物和苯二氮䓬类药物实现。然而,存在非药物干预措施可用于改善患者体验。此外,通过确定在中度镇静下增加患者体验质量的非药物干预措施,面临结肠镜检查中深度镇静使用增加及其相关显著成本的司法管辖区可能能够更好地鼓励患者和临床医生采用中度镇静。推进这两个目标中的任何一个都需要综合证据,并提高对这些非药物干预措施的认识,以改善结肠镜检查的患者体验。
将进行系统评价,该评价将从开始搜索到 2020 年搜索多个电子数据库,以确定评估在中度或无镇静下常规结肠镜检查中与安慰剂或常规护理相比任何非药物干预措施是否有效的随机对照试验。两名审查员将独立进行三阶段筛选过程,并使用试点表格提取所有研究数据。使用 Cochrane 偏倚风险工具 V.2.0 评估研究质量。如果多项研究评估了单一干预措施,则将使用成对荟萃分析对证据进行定量综合,否则将进行叙述性综合。
这是对现有文献的审查,不需要伦理批准。审查结果将纳入未来减少常规结肠镜检查中深度镇静使用的实施策略的努力中。它们还将发表在同行评议的期刊上,在会议上展示,并为博士论文做出贡献。
PROSPERO 注册号:CRD42020173906。